Artivion (NYSE:AORT) Given New $48.00 Price Target at Canaccord Genuity Group

Artivion (NYSE:AORT) had its target price decreased by Canaccord Genuity Group from $51.00 to $48.00 in a research report released on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other brokerages have also recently weighed in on AORT. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price target on shares of Artivion in a research report on Monday, February 2nd. Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Wall Street Zen downgraded shares of Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.69.

Artivion Stock Performance

AORT opened at $36.24 on Friday. Artivion has a 52-week low of $21.97 and a 52-week high of $48.25. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50. The company has a market cap of $1.72 billion, a P/E ratio of 181.18 and a beta of 1.59. The firm’s 50-day moving average price is $43.60 and its 200-day moving average price is $42.79.

Artivion (NYSE:AORT) last released its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.74%. Artivion’s revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, equities analysts anticipate that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity

In other Artivion news, SVP Marshall S. Stanton sold 47,376 shares of the stock in a transaction on Friday, November 21st. The shares were sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the transaction, the senior vice president directly owned 44,753 shares of the company’s stock, valued at $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Amy Horton sold 6,000 shares of Artivion stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $45.73, for a total transaction of $274,380.00. Following the completion of the sale, the chief accounting officer owned 135,380 shares in the company, valued at approximately $6,190,927.40. This trade represents a 4.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 128,448 shares of company stock worth $5,793,361. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in shares of Artivion by 107.0% in the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after buying an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its stake in Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Artivion by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Artivion in the 2nd quarter worth approximately $669,000. Finally, Envestnet Asset Management Inc. lifted its stake in Artivion by 364.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after purchasing an additional 41,487 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.